CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- The complete remission (CR) rate
研究概览
简要总结
This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
详细描述
CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Open Label
入排标准
- 年龄范围
- 10 Years 至 60 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with CD19 positive central nervous system B-cell acute lymphocytic leukemia
- •ALT/ AST 《 3x normal
- •Creatinine 《 3x normal
- •Signed informed consent
排除标准
- •Active hepatitis B , hepatitis C or HIV infection
- •Uncontrolled active infection
- •Pregnancy or breast-feeding women
- •Survival less than four weeks
结局指标
主要结局
The complete remission (CR) rate
时间窗: Participants will be followed for the duration of the treatment, an expected average of 12 months
The safety of the humanized CD19 CAR-T cells treatment will be evalated and the maximum tolerated dose will be determined
次要结局
未报告次要终点
